pharmaphorum

JUNE 23, 2022

The deal comes a year after Intellia and partner Regeneron reported promising results from the first clinical trial of a drug used to edit the genomes of cells within the body, in patients with rare disease ATTR amyloidosis. billion in potential milestones if the project advances through development and onto the market.

Gene Editing 97

Gene Editing In-Vivo Gene Sequencing Gene 97

pharmaphorum

JANUARY 5, 2023

and OriCiro Genomics K.K. The data was from their phase 2b trial of a personalised vaccine consisting of 34 mRNAs, each targeting mutations – identified by gene sequencing – thought to be driving a patient’s cancer. Biotech Moderna, Inc. The deal marks 10-year-old Moderna’s first acquisition.

Gene Sequencing 97

Gene Sequencing DNA Vaccine Vaccination 97

pharmaphorum

MARCH 15, 2022

Gene sequencing specialist Illumina has started rolling out a new test that looks for a battery of tumour-associated genes from a single tissue sample, and could be used to help guide treatment for a broad range of cancers. “Comprehensive genomic profiling has proven to be this platform.”

Gene 52

Gene Genomics Genome Gene Sequencing 52